• SGs are associated with AD through bidirectional interactions with tau pathology, RNA dysregulation, and proteostatic collapse. • SG modulation is a potential therapeutic strategy for AD. • Autophagy enhancers (mTOR inhibitors, myricetin), show promise in reducing tau pathology.
Kashtiban et al. (Mon,) studied this question.